Dr. Clay Siegall is a co-founder of Seattle Genetics since 1998 serving as President, Chief Executive Officer, and Chairman of the Board of Directors. Seattle Genetics is working on antibody-based cancer therapies such as brentuximab vedotin, which became U.S. Food and Drug Administration approved in 2011. As a member of the pharmaceutical industry, Siegall founded Seattle Genetics to work on new scientific breakthroughs, intensive research, and drug development. Brentuximab vedotin is a globally reaching brand available in 65 countries. Seattle Genetics has strategic licenses with Genentech (Roche), AbbVie, GlaxoSmithKline, and Pfizer, generating more than $350 million until now.
It is the goal of Seattle Genetics to help patients. Siegall watched his father die of cancer from the age of 19 to the age of 24. Seattle Genetics works very hard with diverse antibody cancer treatments to come up with better technologies that work to heal cancer. Dr. Siegall has secured $675 million through public and private financing with the first public offering for Seattle Genetics happening in 2001. Siegall has a Ph.D. in genetics from George Washington University as well as a B.S. in Zoology from the University of Maryland. He has authored more than 70 publications and holds at least 15 patents.
Siegall’s treatments work with microRNAs, which are 20-25 nucleotides long, affecting gene expression working with messenger RNAs. 1,400 miRNA are encoded in the human genome structure, which make up 2% of mammal’s genes. New technology is helping treat rare and ultra-rare disease using these nucleotides among other new technologies. The focus is on extremely painful, metabolic based, genetic diseases. The goal is to find tumor suppressors and activate them in cancer patients, as well as other diseases. Dr. Clay Siegall previous work brought him to Bristol-Meyers Squibb and their Pharmaceutical Research Institute from 1991 to 1997 where he learned about how to run a company.